Avid Bioservices Inc (CDMO)

[justmarried]

Merck going to 15th World Conference on Lung Cancer Oct.29, Sydney Australia to discuss interim data on MK-3475-anti PD-1..

seekingalpha.com/news-article/7735512-interim-data-for-merck-s-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-to-be-presented-at-15th-world-conference-on-lung-cancer

Very Interesting, could Bavi be the Big Brother to MK-3475.??[quote]Many tumors are able to evade the immune system through a mechanism that exploits the PD-1 inhibitory checkpoint protein. MK-3475 is an investigational, highly selective anti-PD-1 immunotherapy designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation of the immune systems T-cells that target cancer by essentially releasing a brake on the immune system. [/quote]